Single, Low-dose Course of Rituximab Treats MuSK-MG, Pilot Study Suggests

Single, Low-dose Course of Rituximab Treats MuSK-MG, Pilot Study Suggests

291434

Single, Low-dose Course of Rituximab Treats MuSK-MG, Pilot Study Suggests

A single, two-day and low-dose course of rituximab can effectively treat patients with muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG) over at least six months, according to a pilot study. The low dose administered eased disease symptoms and measures of clinical severity, and enabled patients to lower their steroid doses. The study, “Short Term Effect of Low‐dose Rituximab on Myasthenia Gravis with Muscle‐specific Tyrosine Kinase Antibody,” was published in the journal Muscle & Nerve. Rituximab, sold…

You must be logged in to read/download the full post.